Calcineurin inhibitors or anti-TNF-agents in severe ulcerative colitis: Available options and limitations

Zeitschrift fur Gastroenterologie

Volumn 50, Issue 4, 2012, Pages 396-406

  Bruns, T ^a   Schmidt, C ^a   Stallmach, A ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

bowel; chronic inflammatory bowel disease; ulcerative colitis

Indexed keywords

ADALIMUMAB; CALCINEURIN INHIBITOR; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOSPORIN A; HYDROCORTISONE; INFLIXIMAB; MERCAPTOPURINE; PLACEBO; PREDNISOLONE; STEROID; TACROLIMUS; TUMOR NECROSIS FACTOR INHIBITOR;

ANTIBIOTIC PROPHYLAXIS; ARTICLE; CLINICAL FEATURE; COLITIS; CONTINUOUS INFUSION; CONVULSION; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEVER; GINGIVA DISEASE; HEADACHE; HOSPITALIZATION; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPERTRICHOSIS; HYPOMAGNESEMIA; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LIVER DISEASE; LIVER FUNCTION TEST; NEPHROTOXICITY; NEUROTOXICITY; PARESTHESIA; PATIENT IDENTIFICATION; PERIANAL ABSCESS; PNEUMONIA; PROCTOCOLECTOMY; QUALITY OF LIFE; SALVAGE THERAPY; SEPSIS; SEPTICEMIA; SIDE EFFECT; TOTAL PARENTERAL NUTRITION; TREATMENT FAILURE; TREATMENT PLANNING; TREATMENT RESPONSE; ULCERATIVE COLITIS; URINARY TRACT INFECTION;

CALCINEURIN; COLITIS, ULCERATIVE; GASTROINTESTINAL AGENTS; HUMANS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84859034671     PISSN: 00442771     EISSN: 14397803     Source Type: Journal    
DOI: 10.1055/s-0031-1299299     Document Type: Article

References (100)

1. Edwards FC, Truelove SC. The course and prognosis of ulcerative colitis. Gut: 1963; 4 299 308
2. Sinclair TS, Brunt PW, Mowat NA. Nonspecific proctocolitis in northeastern Scotland: a community study. Gastroenterology: 1983; 85 1 11 (Pubitemid 13106316)
3. Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J: 1955; 2 1041 1048
4. Truelove SC, Jewell DP. Intensive intravenous regimen for severe attacks of ulcerative colitis. Lancet: 1974; 1 1067 1070
5. Turner D, Walsh CM, Steinhart AH et al. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol: 2007; 5 103 110 (Pubitemid 46096828)
6. Faubion WA Jr, Loftus EV Jr, Harmsen WS et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology: 2001; 121 255 260 (Pubitemid 32729372)
7. Lichtiger S, Present DH, Kornbluth A et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med: 1994; 330 1841 1845 (Pubitemid 24188135)
8. Campbell S, Travis S, Jewell D. Ciclosporin use in acute ulcerative colitis: a long-term experience. Eur J Gastroenterol Hepatol: 2005; 17 79 84 (Pubitemid 40128931)
9. Kobayashi T, Naganuma M, Okamoto S et al. Rapid endoscopic improvement is important for 1-year avoidance of colectomy but not for the long-term prognosis in cyclosporine A treatment for ulcerative colitis. J Gastroenterol: 2010; 45 1129 1137
10. Travis S, Satsangi J, Lmann M. Predicting the need for colectomy in severe ulcerative colitis: a critical appraisal of clinical parameters and currently available biomarkers. Gut: 2011; 60 3 9
11. Travis SP, Farrant JM, Ricketts C et al. Predicting outcome in severe ulcerative colitis. Gut: 1996; 38 905 910 (Pubitemid 26231777)
12. Carbonnel F, Lavergne A, Lmann M et al. Colonoscopy of acute colitis. A safe and reliable tool for assessment of severity. Dig DIs Sci: 1994; 39 1550 1557 (Pubitemid 24246449)
13. Dinesen LC, Walsh AJ, Protic MN et al. The pattern and outcome of acute severe colitis. J Crohns Colitis: 2010; 4 431 437
14. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med: 1987; 317 1625 1629 (Pubitemid 18010466)
15. Sandborn WJ, Rutgeerts P, Feagan BG et al. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology: 2009; 137 1250 1260
16. Lau A, Chande N, Ponich T et al. Predictive factors associated with immunosuppressive agent use in ulcerative colitis: a case-control study. Aliment Pharmacol Ther: 2008; 28 606 613
17. Huamn Ros JW, Casellas Jord F, Malagelada Benaprs JR. Predictive factors of poor response to intravenous cyclosporine in steroid-refractory ulcerative colitis. Rev Esp Enferm Dig: 2009; 101 163 171
18. Gulati R, Rawal KK, Kumar N et al. Course of severe ulcerative colitis in northern India. Trop Gastroenterol: 1995; 16 19 23
19. Rutgeerts P, Sandborn WJ, Feagan BG et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med: 2005; 353 2462 2476 (Pubitemid 41770166)
20. Reinisch W, Sandborn WJ, Hommes DW et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut: 2011; 60 780 787
21. Carbonnel F, Gargouri D, Lmann M et al. Predictive factors of outcome of intensive intravenous treatment for attacks of ulcerative colitis. Aliment Pharmacol Ther: 2000; 14 273 279 (Pubitemid 30145314)
22. Lindgren SC, Flood LM, Kilander AF et al. Early predictors of glucocorticosteroid treatment failure in severe and moderately severe attacks of ulcerative colitis. Eur J Gastroenterol Hepatol: 1998; 10 831 835 (Pubitemid 28493257)
23. Maosa M, Cabr E, Garcia-Planella E et al. Decision tree for early introduction of rescue therapy in active ulcerative colitis treated with steroids. Inflamm Bowel Dis: 2011; 17 2497 2502
24. Ho GT, Mowat C, Goddard CJR et al. Predicting the outcome of severe ulcerative colitis: development of a novel risk score to aid early selection of patients for second-line medical therapy or surgery. Aliment Pharmacol Ther: 2004; 19 1079 1087 (Pubitemid 38703520)
25. Van Assche G, D'Haens G, Noman M et al. Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology: 2003; 125 1025 1031 (Pubitemid 37193449)
26. Cacheux W, Seksik P, Lemann M et al. Predictive factors of response to cyclosporine in steroid-refractory ulcerative colitis. Am J Gastroenterol: 2008; 103 637 642 (Pubitemid 351405993)
27. Rowe FA, Walker JH, Karp LC et al. Factors predictive of response to cyclosporin treatment for severe, steroid-resistant ulcerative colitis. Am J Gastroenterol: 2000; 95 2000 2008
28. Aceituno M, Garca-Planella E, Heredia C et al. Steroid-refractory ulcerative colitis: predictive factors of response to cyclosporine and validation in an independent cohort. Inflamm Bowel Dis: 2008; 14 347 352 (Pubitemid 351441323)
29. Holme O, Thiis-Evensen E, Vatn MH. Treatment of fulminant ulcerative colitis with cyclosporine A. Scand J Gastroenterol: 2009; 44 1310 1314
30. Arts J, D'Haens G, Zeegers M et al. Long-term outcome of treatment with intravenous cyclosporin in patients with severe ulcerative colitis. Inflamm Bowel Dis: 2004; 10 73 78 (Pubitemid 38332164)
31. Stack WA, Long RG, Hawkey CJ. Short- and long-term outcome of patients treated with cyclosporin for severe acute ulcerative colitis. Aliment Pharmacol Ther: 1998; 12 973 978 (Pubitemid 28454379)
32. Sharkey L, Bredin F, Nightingale A et al. The use of cyclosporin A in acute steroid-refractory ulcerative colitis: long term outcomes. J Crohns Colitis: 2011; 5 91 94
33. Cheifetz AS, Stern J, Garud S et al. Cyclosporine is safe and effective in patients with severe ulcerative colitis. J Clin Gastroenterol: 2011; 45 107 112
34. Cohen RD, Stein R, Hanauer SB. Intravenous cyclosporin in ulcerative colitis: a five-year experience. Am J Gastroenterol: 1999; 94 1587 1592 (Pubitemid 29260450)
35. Lichtiger S. Treatment of choice for acute severe steroid-refractory ulcerative colitis is cyclosporine. Inflamm Bowel Dis: 2009; 15 141 142
36. Moskovitz DN, Van Assche G, Maenhout B et al. Incidence of colectomy during long-term follow-up after cyclosporine-induced remission of severe ulcerative colitis. Clin Gastroenterol Hepatol: 2006; 4 760 765 (Pubitemid 43833506)
37. Walch A, Meshkat M, Vogelsang H et al. Long-term outcome in patients with ulcerative colitis treated with intravenous cyclosporine A is determined by previous exposure to thiopurines. J Crohns Colitis: 2010; 4 398 404
38. Bamba S, Tsujikawa T, Inatomi O et al. Factors affecting the efficacy of cyclosporin A therapy for refractory ulcerative colitis. J Gastroenterol Hepatol: 2010; 25 494 498
39. Actis GC, Fadda M, David E et al. Colectomy rate in steroid-refractory colitis initially responsive to cyclosporin: a long-term retrospective cohort study. BMC Gastroenterol: 2007; 7 13
40. Baumgart DC, Wiedenmann B, Dignass AU. Rescue therapy with tacrolimus is effective in patients with severe and refractory inflammatory bowel disease. Aliment Pharmacol Ther: 2003; 17 1273 1281 (Pubitemid 36693728)
41. Ogata H, Matsui T, Nakamura M et al. A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut: 2006; 55 1255 1262 (Pubitemid 44277355)
42. Baumgart DC, Macdonald JK, Feagan B. Tacrolimus (FK506) for induction of remission in refractory ulcerative colitis. Cochrane Database Syst Rev: 2008; CD007216
43. Fellermann K, Tanko Z, Herrlinger KR et al. Response of refractory colitis to intravenous or oral tacrolimus (FK506). Inflamm Bowel Dis: 2002; 8 317 324
44. Högenauer C, Wenzl HH, Hinterleitner TA et al. Effect of oral tacrolimus (FK 506) on steroid-refractory moderate/severe ulcerative colitis. Aliment Pharmacol Ther: 2003; 18 415 423 (Pubitemid 37070240)
45. Ogata H, Kato J, Hirai F et al. Double-blind, placebo-controlled trial of oral tacrolimus (FK506) in the management of hospitalized patients with steroid-refractory ulcerative colitis. Inflamm Bowel Dis: 2011; in press 10.1002/ibd.21853
46. Herrlinger KR, Koc H, Winter S et al. ABCB1 single-nucleotide polymorphisms determine tacrolimus response in patients with ulcerative colitis. Clin Pharmacol Ther: 2011; 89 422 428
47. Sands BE, Tremaine WJ, Sandborn WJ et al. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis: 2001; 7 83 88
48. Probert CSJ, Hearing SD, Schreiber S et al. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut: 2003; 52 998 1002 (Pubitemid 36765292)
49. Järnerot G, Hertervig E, Friis-Liby I et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology: 2005; 128 1805 1811 (Pubitemid 40824691)
50. Mortensen C, Caspersen S, Christensen NL et al. Treatment of acute ulcerative colitis with infliximab, a retrospective study from three Danish hospitals. J Crohns Colitis: 2011; 5 28 33
51. Lees CW, Heys D, Ho GT et al. A retrospective analysis of the efficacy and safety of infliximab as rescue therapy in acute severe ulcerative colitis. Aliment Pharmacol Ther: 2007; 26 411 419 (Pubitemid 47063146)
52. Kohn A, Daperno M, Armuzzi A et al. Infliximab in severe ulcerative colitis: short-term results of different infusion regimens and long-term follow-up. Aliment Pharmacol Ther: 2007; 26 747 756 (Pubitemid 47246204)
53. Oussalah A, Evesque L, Laharie D et al. A multicenter experience with infliximab for ulcerative colitis: outcomes and predictors of response, optimization, colectomy, and hospitalization. Am J Gastroenterol: 2010; 105 2617 2625
54. Sandborn WJ, Van Assche G, Reinisch W et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology: 2011; in press 10.1053/j.gastro.2011.10.032
55. D'Haens G, Sandborn WJ, Feagan BG et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology: 2007; 132 763 786
56. Angell M. The Truth About the Drug Companies: How They Deceive Us and What to Do About It. 1st edn New York Random House: 2004
57. Sjöberg M, Walch A, Meshkat M et al. Infliximab or cyclosporine as rescue therapy in hospitalized patients with steroid-refractory ulcerative colitis: A retrospective observational study. Inflamm Bowel Dis: 2011; in press 10.1002/ibd.21680
58. Laharie D, Bourreille A, Branche J et al. Cyclosporin versus infliximab in severe acute ulcerative colitis refractory to intravenous steroids: a randomized trial. Gastroenterology: 2011; 140 S-112
59. Punekar YS, Hawkins N. Cost-effectiveness of infliximab for the treatment of acute exacerbations of ulcerative colitis. Eur J Health Econ: 2010; 11 67 76
60. D'Haens G, Lemmens L, Geboes K et al. Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. Gastroenterology: 2001; 120 1323 1329 (Pubitemid 32322305)
61. Maosa M, Lpez San Romn A, Garcia-Planella E et al. Infliximab rescue therapy after cyclosporin failure in steroid-refractory ulcerative colitis. Digestion: 2009; 80 30 35
62. Maser EA, Deconda D, Lichtiger S et al. Cyclosporine and infliximab as rescue therapy for each other in patients with steroid-refractory ulcerative colitis. Clin Gastroenterol Hepatol: 2008; 6 1112 1116
63. Chaparro M, Burgueno P, Flores EI et al. Efficacy and safety of infliximab rescue therapy after cyclosporine failure in patients with steroid-refractory ulcerative colitis: a multicenter study. Gastroenterology: 2010; 138 S-688
64. Leblanc S, Allez M, Seksik P et al. Successive treatment with cyclosporine and infliximab in steroid-refractory ulcerative colitis. Am J Gastroenterol: 2011; 106 771 777
65. Travis SPL, Stange EF, Lmann M et al. European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut: 2006; 55 01 i16 i35 (Pubitemid 43268291)
66. Dignass A, Preiss JC, Aust DE et al. Updated German guideline on diagnosis and treatment of ulcerative colitis, 2011. Z Gastroenterol: 2011; 49 1276 1341
67. Garca-Lpez S, Gomolln-Garca F, Prez-Gisbert J. Cyclosporine in the treatment of severe attack of ulcerative colitis: a systematic review. Gastroenterol Hepatol: 2005; 28 607 614
68. Bruns T, Stallmach A. Drug monitoring in inflammatory bowel disease: helpful or dispensable? Dig Dis: 2009; 27 394 403
69. Lichtenstein GR, Feagan BG, Cohen RD et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol: 2006; 4 621 630
70. Fidder H, Schnitzler F, Ferrante M et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut: 2009; 58 501 508
71. Toruner M, Loftus EV, Harmsen WS et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology: 2008; 134 929 936 (Pubitemid 351451967)
72. Lin MV, Pascua MF, Aberra F et al. The use of immunosuppressive medications as risk factor for non-opportunistic infectious complications in patients with IBD. Gastroenterology: 2009; 136 A-660
73. Rahier JF, Ben-Horin S, Chowers Y et al. European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis: 2009; 3 47 91
74. Stallmach A, Hagel S, Bruns T. Adverse effects of biologics used for treating IBD. Best Pract Res Clin Gastroenterol: 2010; 24 167 182
75. Subramanian V, Saxena S, Kang J-Y et al. Preoperative steroid use and risk of postoperative complications in patients with inflammatory bowel disease undergoing abdominal surgery. Am J Gastroenterol: 2008; 103 2373 2381
76. Ferrante M, D'Hoore A, Vermeire S et al. Corticosteroids but not infliximab increase short-term postoperative infectious complications in patients with ulcerative colitis. Inflamm Bowel Dis: 2009; 15 1062 1070
77. Colombel JF, Loftus EV, Tremaine WJ et al. Early postoperative complications are not increased in patients with Crohn's disease treated perioperatively with infliximab or immunosuppressive therapy. Am J Gastroenterology: 2004; 99 878 883 (Pubitemid 39090217)
78. Gainsbury ML, Chu DI, Howard LA et al. Preoperative infliximab is not associated with an increased risk of short-term postoperative complications after restorative proctocolectomy and ileal pouch-anal anastomosis. J Gastrointest Surg: 2011; 15 397 403
79. Kunitake H, Hodin R, Shellito PC et al. Perioperative treatment with infliximab in patients with Crohn's disease and ulcerative colitis is not associated with an increased rate of postoperative complications. J Gastrointest Surg: 2008; 12 1730 1737
80. Marchal L, D'Haens G, Van Assche G et al. The risk of post-operative complications associated with infliximab therapy for Crohn's disease: a controlled cohort study. Aliment Pharmacol Ther: 2004; 19 749 754 (Pubitemid 38496640)
81. Mor IJ, Vogel JD, da Luz Moreira A et al. Infliximab in ulcerative colitis is associated with an increased risk of postoperative complications after restorative proctocolectomy. Dis Colon Rectum: 2008; 51 1202 1210
82. Selvasekar CR, Cima RR, Larson DW et al. Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis. J Am Coll Surg: 2007; 204 956 962 (Pubitemid 46661200)
83. Yang Z, Wu Q, Wu K et al. Meta-analysis: pre-operative infliximab treatment and short-term post-operative complications in patients with ulcerative colitis. Aliment Pharmacol Ther: 2010; 31 486 492
84. Schluender SJ, Ippoliti A, Dubinsky M et al. Does infliximab influence surgical morbidity of ileal pouch-anal anastomosis in patients with ulcerative colitis? Dis Colon Rectum: 2007; 50 1747 1753 (Pubitemid 350077092)
85. Hanauer SB. Inflammatory bowel disease. N Engl J Med: 1996; 334 841 848 (Pubitemid 26099608)
86. Santos J, Baudet S, Casellas F et al. Efficacy of intravenous cyclosporine for steroid refractory attacks of ulcerative colitis. J Clin Gastroenterol: 1995; 20 285 289
87. Fernndez-Baares F, Bertrn X, Esteve-Comas M et al. Azathioprine is useful in maintaining long-term remission induced by intravenous cyclosporine in steroid-refractory severe ulcerative colitis. Am J Gastroenterol: 1996; 91 2498 2499 (Pubitemid 26406297)
88. Carbonnel F, Boruchowicz A, Duclos B et al. Intravenous cyclosporine in attacks of ulcerative colitis: short-term and long-term responses. Dig Dis Sci: 1996; 41 2471 2476
89. Van Gossum A, Schmit A, Adler M et al. Short- and long-term efficacy of cyclosporin administration in patients with acute severe ulcerative colitis. Belgian IBD Group. Acta Gastroenterol Belg: 1997; 60 197 200 (Pubitemid 27489427)
90. Hyde GM, Thillainayagam AV, Jewell DP. Intravenous cyclosporin as rescue therapy in severe ulcerative colitis: time for a reappraisal? Eur J Gastroenterol Hepatol: 1998; 10 411 413 (Pubitemid 28241428)
91. Actis GC, Lagget M, Rizzetto M et al. Long-term efficacy of oral microemulsion cyclosporin for refractory ulcerative colitis. Minerva Med: 2004; 95 65 70 (Pubitemid 38667805)
92. Message L, Bourreille A, Laharie D et al. Efficacy of intravenous cyclosporin in moderately severe ulcerative colitis refractory to steroids. Gastroenterol Clin Biol: 2005; 29 231 235 (Pubitemid 40516308)
93. Yamamoto S, Nakase H, Mikami S et al. Long-term effect of tacrolimus therapy in patients with refractory ulcerative colitis. Aliment Pharmacol Ther: 2008; 28 589 597
94. Benson A, Barrett T, Sparberg M et al. Efficacy and safety of tacrolimus in refractory ulcerative colitis and Crohn's disease: a single-center experience. Inflamm Bowel Dis: 2008; 14 7 12 (Pubitemid 351196862)
95. Molnr T, Farkas K, Nyri T et al. Long-term efficacy and safety of cyclosporine as a rescue therapy in acute, steroid-refractory severe ulcerative colitis: switching to infliximab is more effective than treating with concomitant immunomodulators. J Clin Gastroenterol: 2011; 45 380 381
96. Naganuma M, Fujii T, Watanabe M. The use of traditional and newer calcineurin inhibitors in inflammatory bowel disease. J Gastroenterol: 2011; 46 129 137
97. Afif W, Leighton JA, Hanauer SB et al. Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab. Inflamm Bowel Dis: 2009; 15 1302 1307
98. Taxonera C, Estells J, Fernndez-Blanco I et al. Adalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximab. Aliment Pharmacol Ther: 2011; 33 340 348
99. Yamamoto S, Nakase H, Matsuura M et al. Efficacy and safety of infliximab as rescue therapy for ulcerative colitis refractory to tacrolimus. J Gastroenterol Hepatol: 2010; 25 886 891
100. Herrlinger KR, Barthel DN, Schmidt KJ et al. Infliximab as rescue medication for patients with severe ulcerative/indeterminate colitis refractory to tacrolimus. Aliment Pharmacol Ther: 2010; 31 1036 1041